Trial Profile

Phase 2B Study of Memantine for the Treatment of Amyotrophic Lateral Sclerosis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Memantine (Primary)
Indications Amyotrophic lateral sclerosis
Focus Therapeutic Use
Acronyms TAME

Most Recent Events

25 Dec 2024 Results assessing memantine's effect on ALS progression were published in the Muscle and Nerve.
25 Oct 2021 Status changed from recruiting to completed.
07 Nov 2018 Planned End Date changed from 1 Oct 2021 to 1 Oct 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com